China Resources Pharmaceutical Group Limited (abbreviated as CHINARES PHARMA) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the second tranche of its 2026 corporate bonds in mainland China.

The issuance raised RMB0.90 billion through three-year bonds carrying a fixed annual coupon of 1.48%. According to the filing, net proceeds will be allocated to production spending, repayment of existing debt, working-capital replenishment, project development and operational outlays, as well as investments in scientific and technological innovation, all in compliance with relevant regulations.

Management reiterated that shareholders and potential investors should exercise caution when trading the company’s securities.